Advancing Translational Models of Cancer Cachexia for Preclinical-to-Clinical Integration

Cancer cachexia is a devastating metabolic syndrome characterized by progressive weight loss, skeletal muscle wasting, and reduced tolerance to anticancer therapies. GemPharmatech has established and validated multiple preclinical models that closely recapitulate key features of human cancer cachexia. In HT-1080 xenograft models, tumor-bearing mice exhibited progressive body weight loss, anorexia, and depletion of muscle and fat mass. Treatment with the anti-GDF15 neutralizing antibody Ponsegromab effectively reversed these cachectic symptoms. Complementary syngeneic, xenograft, and chemotherapy-induced cachexia models further confirmed the robustness of these platforms. These well-characterized models provide valuable translational tools for elucidating cachexia mechanisms and evaluating novel therapeutic interventions.